IceCure Medical Q3 EPS Reduced by Brookline Capital Markets

IceCure Medical Ltd. (NASDAQ:ICCM) – Research analysts at Brookline Capital Markets lowered their Q3 2026 EPS estimates for shares of IceCure Medical in a report released on Wednesday, August 12th. Brookline Capital Markets analyst K. Dolliver now expects that the company will post earnings per share of ($0.83) for the quarter, down from their prior forecast of ($0.56). The consensus estimate for IceCure Medical’s current full-year earnings is ($4.61) per share. Brookline Capital Markets also issued estimates for IceCure Medical’s Q4 2026 earnings at ($0.84) EPS, FY2026 earnings at ($4.61) EPS, FY2027 earnings at ($3.61) EPS, FY2028 earnings at ($2.26) EPS and FY2029 earnings at $0.41 EPS.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($1.64) EPS for the quarter. IceCure Medical had a negative return on equity of 174.26% and a negative net margin of 427.67%.The company had revenue of $0.91 million for the quarter.

Other analysts have also recently issued research reports about the company. Alliance Global Partners initiated coverage on IceCure Medical in a research report on Monday, May 4th. They set a “buy” rating on the stock. Zacks Research cut IceCure Medical from a “hold” rating to a “strong sell” rating in a research report on Friday, August 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a research report on Friday, July 17th. Maxim Group dropped their price target on IceCure Medical from $90.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Finally, Wall Street Zen raised IceCure Medical to a “sell” rating in a research report on Sunday, July 12th. Three investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $52.50.

IceCure Medical Price Performance

NASDAQ ICCM opened at $2.60 on Monday. IceCure Medical has a 1 year low of $2.12 and a 1 year high of $42.00. The company has a market capitalization of $8.91 million, a PE ratio of -0.31 and a beta of 0.47. The company has a fifty day moving average of $3.91 and a two-hundred day moving average of $9.49.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ICCM. Jane Street Group LLC acquired a new stake in shares of IceCure Medical during the fourth quarter worth about $67,000. Concurrent Investment Advisors LLC acquired a new position in IceCure Medical in the 4th quarter valued at about $48,000. Finally, Virtu Financial LLC acquired a new position in IceCure Medical in the 4th quarter valued at about $39,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.